isatuximab,carfilzomib,lenalidomide,dexamethasone
sanofi,amgen
nct04934475: phase 3 - ifm 2020-02 minimal residual disease adapted strategy (midas) krd-isatuximab #mmsm #multiplemyeloma #ims2022 
Multiple Myeloma Education Platform for Myeloma Community